VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia
Open Access
- 3 March 2026
- journal article
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2) , 100146
Abstract
No abstract availableKeywords
Funding Information
- American Heart Association (23PRE1019986)
- American Heart Association (24CDA1276922)
- National Heart, Lung, and Blood Institute (HL007853)
- University of Michigan
- National Institute of General Medical Sciences (GM131835)
- National Institute of General Medical Sciences (GM140223)
- W. W. Smith Charitable Trust
- National Institutes of Health
This publication has 33 references indexed in Scilit:
- Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatmentExpert Review of Hematology, 2021
- DHA 12‐LOX‐derived oxylipins regulate platelet activation and thrombus formation through a PKA‐dependent signaling pathwayJournal of Thrombosis and Haemostasis, 2020
- Pathogenesis of heparin-induced thrombocytopeniaTranslational Research, 2020
- Blood clot parameters: Thromboelastography and scanning electron microscopy in research and clinical practiceThrombosis Research, 2017
- Clinical outcomes in a cohort of patients with heparin‐induced thrombocytopeniaAmerican Journal of Hematology, 2017
- Antiplatelet drugs: which targets for which treatments?Journal of Thrombosis and Haemostasis, 2015
- ArgatrobanJournal of Thrombosis and Thrombolysis, 2002
- Dynamic Aspects Of Platelet Adhesion Under FlowClinical and Experimental Pharmacology and Physiology, 2001
- Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced ThrombocytopeniaThrombosis and Haemostasis, 1992
- Arterial Embolism Occurring During Systemic Heparin TherapyArchives of Surgery, 1958